CurrentUnitedHealthcarePolicy N/A

Prior authorization checklist for non-preferred anemia drugs

This document governs prior authorization/submission requirements for non-preferred drugs indicated for various types of anemia and identifies clinical documentation the prescriber must provide.

Policy Summary

PayerUnitedHealthcare

PolicyPrior authorization checklist for non-preferred anemia drugs

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionComplete the prior-authorization checklist documenting prior preferred-drug failures, recent lab (within 3 months) with hemoglobin value, dosing details, and prescriber signature.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7indications listed

3lab recency (months)

2preferred-drug failures

180max therapy days

Coverage and Medical Necessity Criteria

Prior Authorization Criteria

Covered when ALL of the following are met

Prior therapy: Failed two preferred drugs; if only one preferred drug is available, then failed one preferred drug.2 (or 1 if only one preferred exists)

Document failures in checklist (see Clinical Information: Failed two preferred drugs).

Documentation: Provider submits diagnosis/indication (select from anemia etiologies listed), lab test date within last 3 months with hemoglobin value, dosage and frequency, drug name/strength/quantity, requested length of therapy, prescriber signature, beneficiary identifiers, and prescriber NPI.Lab test date within the last 3 months

See checklist fields on form (Diagnosis options; Lab Test Date; Hemoglobin; Dosage; Length of Therapy; Prescriber signature).

Policy Summary

PayerUnitedHealthcare

PolicyPrior authorization checklist for non-preferred anemia drugs

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionComplete the prior-authorization checklist documenting prior preferred-drug failures, recent lab (within 3 months) with hemoglobin value, dosing details, and prescriber signature.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Clinical justification for non-preferred use: Document one or more of: allergic reaction (with reaction described), drug–drug interaction (listed), previous unacceptable side effect or therapeutic failure, clinical contraindication or comorbidity, age-specific indication, unique FDA- or literature-supported indication, or unacceptable clinical risk associated with therapeutic change.

Enter details in checklist fields on the form.

This prior authorization checklist must be completed for requests for non-preferred anemia therapies. The form documents prior therapy, current diagnosis, recent laboratory data, dosing information, and administrative attestations. Key required items include documentation of prior preferred‑drug trials (see checklist for failures), the specific diagnosis/indication selected from the provided list, a lab test date within the last 3 months with the current hemoglobin value, drug name/strength/quantity, dosage and frequency, requested length of therapy, and the prescriber’s signature and NPI.

The form does not enumerate separate, named conditions that are universally considered not medically necessary. Instead, authorization may be denied when the checklist requirements are not met — for example, when the required documentation of prior preferred‑drug failure(s), diagnosis/indication selection, or a lab test date and hemoglobin value within the last 3 months are absent. Providers should complete all checklist fields (including reason for non‑preferred use such as allergic reaction, drug‑drug interaction, prior therapeutic failure, or clinical contraindication) to avoid administrative denial.

Laboratory and Coding Requirements

Lab recency — required test date and hemoglobin value

RequirementLab test date must be within the last 3 months (provider must record date and hemoglobin value).

Where recordedChecklist field: 'Lab Test Date Within the Last 3 Months? Date:' with adjacent 'Hemoglobin' entry.

PurposeVerifies current anemia status to support medical necessity for non-preferred therapy.

EnforcementRequests lacking a lab date within 3 months and hemoglobin value may be denied for insufficient documentation.

Prescriber Responsibilities and Submission Checklist

Prior Authorization

Checklist-based prior authorization — completion required

For requests for non-preferred drugs, the prescriber must document prior therapy and clinical justification. Failure to provide required documentation or to show prior preferred-drug trials may result in denial.

Checklist documenting prior preferred-drug failures and therapy details (dates, agents, doses, duration)
If only one preferred drug exists, documentation of failure of that single preferred agent is sufficient
Clinical rationale for use of non-preferred drug (see items below)
Prescriber signature and contact information (NPI, phone, date)

Step Therapy

Preferred-drug failure requirement (step-therapy)

Step-therapy is enforced: the patient must have failed two preferred drugs prior to approval of a non-preferred agent, unless only one preferred drug exists (then one failure is required). Document specific agents tried, dates, doses, and reason for failure (lack of efficacy, adverse reaction, intolerance).

List each preferred agent tried with start/stop dates
State reason for discontinuation or failure (e.g., lack of efficacy, adverse event)
If only one preferred drug is on the formulary, document failure of that single agent

Documentation Required

Required clinical and administrative documentation

Required clinical and administrative documentation must accompany the request. Include lab results, diagnosis, indication, dosing, and any clinical contraindications to preferred therapies.

Diagnosis/indication for the product (e.g., anemia associated with renal failure, chemotherapy, HIV, MDS, sickle cell disease, drug-induced anemia)
Lab test date within the last 3 months and result (e.g., hemoglobin and date)
Dosage, strength, quantity per 30 days, frequency, and requested length of therapy
Clinical reasons why preferred drugs are not appropriate (allergy with reaction description, drug–drug interaction, previous unacceptable side effect or therapeutic failure, comorbidity or contraindication, age-specific indication, FDA/peer-reviewed support for unique indication, unacceptable clinical risk with therapeutic change)
Complete patient identifiers (name, beneficiary ID, DOB, gender)
Prescriber NPI, contact name, phone, and prescriber signature (signature mandatory)

Denial Risk

Missing documentation or prior therapy failure — denial risk

Missing documentation or lack of documented prior therapy failures is a denial risk. Requests that do not include completed checklist items, evidence of preferred-drug trials, or required labs and prescriber signature may be returned or denied.

Incomplete checklist or missing reasons for preferred-drug failure may cause denial
Absence of recent lab results (within 3 months) or missing diagnosis/indication increases denial likelihood
Unsigned requests or missing prescriber NPI/contact details are administratively incomplete

Clinical Background

Anemia in the checklist is presented as a heterogeneous clinical problem with multiple etiologies. The form lists the following selectable indications: anemia associated with renal failure, anemia associated with HIV infection, anemia associated with chemotherapy, anemia associated with myelodysplastic syndromes, drug‑induced anemia (e.g., ribavirin or zidovudine), and sickle cell disease. Management decisions and justification for non‑preferred agents should reference the specific diagnosis selected on the form and relevant prior treatment history or contraindications.

Key Terms and Definitions

Non-preferred drug — definition and PA implication

DefinitionA medication not listed as preferred on the payer's drug list that requires additional clinical justification documented on the non-preferred drug checklist.

Implication for prior authorizationPrior authorization requires completion of the checklist documenting prior preferred-drug failures and clinical justification (allergies, interactions, therapeutic failure, contraindications, etc.) to authorize a non-preferred drug.

Documentation neededProvider must supply diagnosis/indication, recent lab and hemoglobin, dosage/frequency, drug name/strength/quantity, length of therapy, prescriber signature, beneficiary identifiers, and prescriber NPI.

Step-therapy roleNon-preferred drugs will be authorized only after required trials of preferred agents are documented (see preferred-drug failure requirement).

Preferred-drug failure — definition

DefinitionFailure of one or more preferred agents due to therapeutic failure, unacceptable side effect, allergic reaction, or contraindication—documented on the checklist.

Required evidenceChecklist items include: allergic reaction (describe), drug–drug interaction (list), previous unacceptable side effect or therapeutic failure (describe), clinical contraindication or comorbidity, age-specific indication, or unique FDA/literature-supported indication.

Quantity requiredGeneral policy: failed two preferred drugs are required; if only one preferred drug is available, documented failure of one is acceptable.

Consequence of missing documentationFailure to document preferred-drug failures (two, or one if only one preferred exists) may result in denial of the request.